MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

The limitations of currently available therapies for immune thrombocytopenia (ITP) mean that long-term responses are ...

National running events like the London Marathon and Great North Run inspire thousands of armchair viewers to get healthy, according to new figures released by the NHS today. Visits to the NHS couch ...

Additionally, Novartis AG (NYSE:NVS) is investing in advanced technologies such as digital health, artificial intelligence, and data analytics to improve drug development and patient outcomes.

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...